Together we Drive the Future

Biomarker Summit
Date: March 27 - 28, 2018
Venue: San Diego, CA USA

Choose your language
Traditional Chinese
Simplified Chinese

Dear Colleague,

The Biomarker Summit 2018, to be held on March 27-28, 2018 in San Diego, CA at the Omni San Diego Hotel, is a meeting place for leaders in the field to discuss the issues and challenges scientists and researchers face in all aspects of the biomarker and diagnostic development process from discovery to translation to commercialization.

Topics to be covered:

A wide variety of important topics will be covered including biomarker identification, validation, and translation strategies, bioinformatics and systems biology approaches to personalized medicine, big data analytics and management, regulatory and reimbursement trends, companion diagnostics development, and much more. Through scientific presentations, case studies and panel discussions, these areas will be addressed in an intimate and highly interactive environment with perspectives from industry, academia and the public sector.

Assembling leading scientists, researchers, decision-makers and other players across the industry spectrum, the Summit provides a unique opportunity to gain the latest biomarker developments in four major therapeutic areas, formally organized in the following tracks:

Joint Plenary Sessions:

  1. Opening Keynote Session – Historical Perspective & Current State of the Industry
  2. Round Table Discussions – Neuroinflammation, Neuroimaging and Translational Biomarkers
  3. Lunch Session: Big Data Analytics & Bioinformatics for Biomarkers Development
  4. Award Ceremony & Closing Keynote Session – Predictions for future

Oncology Biomarkers

  1. Immuno-Oncology Biomarkers
  2. Circulating Tumor Cells, Microvesicles, DNA and RNA

Neurological Biomarkers

  1. Biomarkers for Early Identification of Neurological Disease
  2. Monitoring Progression and Treatment Efficacy using Biomarkers

Inflammatory & Immunological Biomarkers

  1. Biomarkers for Early Progressive Inflammatory & Immunological Diseases
  2. Biomarkers as Surrogate Endpoints for Clinical Trials

Cardiovascular Biomarkers

  1. Biomarkers for Heart Failure & Acute Coronary Syndrome
  2. Biomarkers for Metabolic Syndrome & Cardiovascular Risk


We hope to see you there!

Best regards,

The 2018 Advisory Committee

Andreas Jeromin, Quanterix
Andrew Penn, Victoria General Hospital
Bruce W.M.Jordan, Roche Diagnostics
Cristina Stefan, Roche
Daniel Chelsky, Caprion Biosciences
Frédéric Baribaud, Janssen
Gary Gustavsen, Health Advances
Mark Frasier, Michael J. Fox Foundation
Michael Heller, University of California, San Diego
Parag Mallick, Stanford University
Pierluigi Mauri, Proteomics and Metabolomics Laboratory – CNR, Institute for Biomedical Tecnologies (ITB-CNR)
Stephen Pennington, University College Dublin

Supporting Sponsor

Program Partners


Media Partners